ANAHEIM, Calif., Oct. 21, 2014 /PRNewswire/ -- Influenza will
affect as many as 200,000 people this year and with flu-associated
deaths in the United States as
high as 49,000 people. The main way that influenza viruses
are thought to spread is from person to person in respiratory
droplets of coughs and sneezes.
Ebola has a serve way of death, but kills much fewer people each
year than the Flu. The transmission of Ebola is also done by human
fluids including sweat, saliva, blood and other bodily fluids. The
Ebola virus can spread fast with improper testing or slow testing.
As with the flu, both diseases need to be caught early to give the
best results in treatment.
WholeHealth Products' Rapid Influenza Combination Test detects
both Influenza A and Influenza B at the same time.
The Influenza A Test is a visual and rapid assay for the
presumptive qualitative detection of influenza Type A antigens from
nasal washes and aspirates. The influenza B Test utilizes
monoclonal antibodies against Influenza Type B viral
nucleoproteins. The test begins with a extraction of Type B
nucleoproteins. Extracted specimens are then added to the test
device. If type B nucleoproteins are present, they bind to the
antibody-gold conjugate in the test membrane and form a complex.
This complex migrates across the membrane and is captured by type B
antibody in the membrane.
The test takes only 15 minutes.
This test is for professional use only.
Inspired by its slogan, "Love Life Live Long,"
WholeHealth Products is committed to building long term
relationships with the medical and healthcare professional and the
patients, helping saves lives.
www.wholehealth-products.com
WholeHealth Products is your partner in the "Business of
Science".
Headquartered in Anaheim, California,
WholeHealth Products. (OTC:
GWPC) is a diversified company. WholeHealth Products' has a line of more 20 professional
diagnostic tests for hospitals, doctors, clinics and healthcare
centers.
Certain information set forth in this fact sheet may contain
forward-looking statements that involve substantial known and
unknown risks and uncertainties. These forward-looking statements
are subject to numerous risks and uncertainties, certain of which
are beyond the control of WholeHealth Products Inc, including, but
not limited to, risks associated with the impact of general
economic conditions, industry conditions, dependence upon
regulatory approvals, and the uncertainty of obtaining additional
financing. Readers are cautioned that the assumptions used in the
preparation of such information, although considered reasonable at
the time of preparation, may prove to be imprecise and, as such,
undue reliance should not be placed on forward-looking
statements.
Photo - http://photos.prnewswire.com/prnh/20141021/153472
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wholehealth-products-is-proud-to-be-releasing-its-influenza-a-and-b-combo-test-on-the-heels-of-the-announcing-of-its-phase-2-completion-of-the-rapid-ebola-test-413346645.html
SOURCE WholeHealth Products Inc.
